A COMPARISON OF NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES ACT WITH DRUGS AND COSMETICS ACT: SALIENT DIFFERENCES
Journal Title: International Journal of Drug Regulatory Affairs - Year 2017, Vol 5, Issue 3
Abstract
This article assesses the comparison of Narcotic Drugs and Psychotropic Substances Act (NDPS Act) with the Drug and Cosmetic Act (D & C Act) and also point out the salient features of NDPS Act. Drugs and Cosmetics Act, 1940 is a life-saving statue. It was enacted with an objective to regulate the import, manufacture, distribution and sale of drugs and cosmetics without licensing. Domestic legislation for regulating narcotic drugs and psychotropic substances in India has come in the form of NDPS Act, 1985, with an objective to limit the use of these substances and to prevent the abuse of these drugs. Both the aforesaid acts regulate narcotic drugs and psychotropic substances but the NDPS Act is special and strictest legislation for these substances. Stringent provisions of this act are examined in depth like minimum mandatory sentence of ten years and fine of one lakh rupees, offences are cognizable and non-bailable, consumption of drugs is also punishable offence, death sentence for certain repeat offences, attempt to commit an offence would be punishable with similar sentence as provided for that offence, power to tender immunity from prosecution, etc. In this article the authors provides some necessary recommendations in D & C Act on the basis of NDPS Act and also highlights some lacunas in both acts which need to be overcome.
Authors and Affiliations
Vikaas Budhwaar, Vaishali Pruthi, Arun Nanda, Manjusha Choudhary, Prateek G
Keywords
Related Articles
- EP ID EP326754
- DOI 10.22270/ijdra.v5i3.202
- Views 158
- Downloads 0
Requirements for introducing Medical devices in India and US market - A comparative study of regulations
Medical devices are widely used in the healthcare sector and are manufactured by the pharmaceutical industry. The Government of India has periodically come out with certain guidelines, to be followed by the companies tha...
Drug approval process in India and Europe
Every time a new drug is developed it requires a great amount of research work in manufacturing, Pre- clinical Science, Controls, Chemistry & Clinical trials. Regulatory agencies have Drug Reviewers who has the responsib...
GLOBAL REGULATORY APPROACH TOWARDS M-HEALTH
The past decade has witnessed rapid advancement in telecommunication and computer technologies. The smart phone is one result of that technological development and has been adopted by hundreds of millions of people world...
Registration of Drug Product dossier application as per EU Guidelines
Due to variations in the regulatory norms of registration dossier in different countries, there is a strong need for harmonization by ICH for approval of drugs. Generic drugs in EU are approved under the Marketing Author...
SCALE UP AND POSTAPPROVAL CHANGES (SUPAC) GUIDANCE FOR INDUSTRY: A REGULATORY NOTE
In today scenario, as per market demand there is definitely carry out an increment or decrease in production, this is called SUPAC. Different guidelines are provided for those different types of SUPAC in by different reg...